Teleflex’s Board of Directors announced the appointment of Stuart Randle as Interim President and Chief Executive Officer, effective immediately. Randle, who has served on the Board since 2009 and brings over 35 years of medical-device leadership experience—including CEO tenures at Ivenix and GI Dynamics—succeeds Liam Kelly. Concurrently, Dr. Stephen Klasko, previously Lead Director, has been named Chairman of the Board. The Board has retained Spencer Stuart to lead a comprehensive search for a permanent CEO, reflecting its commitment to stable governance and strategic continuity during this transition.

Under the outgoing leadership, Teleflex announced the intended sale of its Acute Care, Interventional Urology and OEM businesses. The Board emphasizes that these transactions will streamline the company’s operations and sharpen its focus on core high-acuity hospital markets, including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access and urology. Management projects that the divestitures, once completed, will position Teleflex for accelerated growth in its remaining therapeutic areas and enhance its return on invested capital.

Based on preliminary results, Teleflex now expects full year 2025 revenues of approximately $3.270 billion to $3.278 billion, down from prior guidance of $3.305 billion to $3.320 billion. The downward revision reflects softer end-user demand for intra-aortic balloon pumps and catheters in the U.S. and Asia during the fourth quarter, delayed OEM purchase orders and lower order volumes in select portfolio segments. These figures remain subject to finalization through quarter-end close, management review and external audit procedures, with full results slated for release in late February or early March 2026.

Teleflex’s leadership transition and updated revenue outlook underscore the company’s evolving strategic priorities. Investors should note the potential near-term headwinds from divestiture execution and product-specific demand fluctuations, balanced by management’s projection of improved margin profiles and cash-flow generation from a more concentrated portfolio. The ongoing CEO search and finalization of 2025 results will be key catalysts, as will the successful integration of recent cost-efficiency initiatives and the realization of synergies in core critical-care and high-acuity hospital markets.